Biotechnology Company Announces Promising Data From Advanced Pancreatic Cancer Study

XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comprising ONIVYDE (ON), 5-Fluorouracil (5FU), and Leucovorin (LV). This chemotherapy regimen is commonly employed in treating pancreatic cancer but is associated with challenging toxicities and suboptimal survival outcomes. Natrunix was evaluated not only as an anti-cancer agent but also for its potential to enhance the tolerability of the chemotherapy. $XBiotech (XBIT.US)$